Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13181779 | 0.94 | ACACB (0.47) | ACACBHDAC6HDAC8LIPESRD5A1 | |
| SCHEMBL12922780 | 0.88 | NAMPT (0.49) | ACACBHDAC6HDAC8SRD5A1SRD5A2 | |
| SCHEMBL3307342 | 0.84 | DRD1 (0.51) | ACACBHDAC6HDAC8LIPESRD5A1 | |
| SCHEMBL20178664 | 0.82 | HDAC6 (0.51) | ACACBHDAC6HDAC8LIPESRD5A1 | |
| SCHEMBL12608358 | 0.81 | HDAC6 (0.50) | ACACBHDAC6HDAC8SRD5A1SRD5A2 | |
| SCHEMBL12682930 | 0.81 | HDAC6 (0.56) | ACACBHDAC6HDAC8NAMPTMAPK1 | |
| SCHEMBL31276014 | 0.81 | HDAC6 (0.56) | ACACBHDAC6HDAC8NAMPTMAPK1 | |
| SCHEMBL1027755 | 0.81 | HDAC6 (0.56) | ACACBHDAC6HDAC8NAMPTMAPK1 | |
| SCHEMBL1263724 | 0.81 | HDAC6 (0.53) | ACACBHDAC6HDAC8NAMPTALDH1A1 | |
| SCHEMBL3879495 | 0.80 | ACACB (0.54) | ACACBHDAC6HDAC8LIPESRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-2445340-B1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8778931-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012088015-A2 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010151318-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749996-B2 | Heterotricyclic metalloprotease inhibitors | Alantos Pharmaceutical Holdings, Inc. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDINGS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165316-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ACACB 190/4885HDAC6 1/4885HDAC8 10/4885 |
| US-20100087420-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | ACACB 1916/4885HDAC6 145/4885HDAC8 37/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | ACACB 4485/4885HDAC6 1165/4885HDAC8 1646/4885 |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ACACB 442/4885HDAC6 1/4885HDAC8 11/4885 |
| US-20100249102-A1 | Heterotricyclic Metalloprotease Inhibitors | MMP13, MMP3, TIMP3 | ACACB 1916/4885HDAC6 145/4885HDAC8 37/4885 |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ACACB 442/4885HDAC6 1/4885HDAC8 11/4885 |
| US-20080207607-A1 | Heterotricyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ACACB 1916/4885HDAC6 145/4885HDAC8 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.